Ceremony to commemorate recent FDA clearance milestone for
Company's Evo® sEEG Electrode technology
EDEN
PRAIRIE, Minn., Nov. 22,
2022 /PRNewswire/ -- NeuroOne Medical Technologies
Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused on improving surgical care options and
outcomes for patients suffering from neurological disorders,
announced today that it will ring the Nasdaq closing bell today
Tuesday, November 22, 2022, to
commemorate its recent corporate milestone achievement for the Evo®
thin film electrode platform.
The NeuroOne closing bell ceremony will be broadcast live
starting at 3:50 p.m. Eastern Time
from Nasdaq MarketSite in New York
City's Times Square. The live broadcast may be viewed
on Livestream and Facebook. Following an
introduction by Nasdaq, NeuroOne CEO Dave
Rosa will deliver brief remarks and then ring the bell
at 4:00 p.m. alongside other members of
the NeuroOne team.
Dave Rosa commented, "Last month
we received FDA 510(k) clearance to market our Evo sEEG Electrode
technology for temporary (less than 30 days) use with equipment for
the recording, monitoring, and stimulation of electrical signals at
the subsurface level of the brain. This was our Company's most
exciting achievement to date, rounding out the full functionality
of our Evo sEEG System* and advancing our manufacturing ramp and
commercialization efforts for this advanced line of diagnostic
electrodes. We are excited to celebrate this victory at Nasdaq's
iconic bell ringing ceremony."
*Caution: Federal law restricts this device to sale by or on the
order of a physician.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information, visit www.n1mtc.com.
Forward Looking
Statements
This press release may include forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Except for statements of historical fact, any information
contained in this presentation may be a forward–looking statement
that reflects NeuroOne's current views about future events and are
subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some
cases, you can identify forward–looking statements by the words or
phrases "may," "might," "will," "could," "would," "should,"
"expect," "intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target," "seek,"
"contemplate," "continue, "focused on," "committed to" and
"ongoing," or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Forward–looking statements may include statements regarding our
manufacturing ramp and commercialization activities. Although
NeuroOne believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that the partnership with Zimmer Biomet may not
facilitate the commercialization or market acceptance of our
technology; risks that our sEEG electrodes may not be ready for
commercialization in a timely manner or at all, whether due to
supply chain disruptions, labor shortages, the impact of COVID-19
or otherwise; risks that our technology will not perform as
expected based on results of our pre-clinical and clinical trials;
risks related to uncertainties associated with the Company's
capital requirements to achieve its business objectives and ability
to raise additional funds; the risk that the COVID-19 pandemic will
continue to adversely impact our business; the risk that we may not
be able to secure or retain coverage or adequate reimbursement for
our technology; uncertainties inherent in the development process
of our technology; risks related to changes in regulatory
requirements or decisions of regulatory authorities; that we may
not have accurately estimated the size and growth potential of the
markets for our technology; risks relate to clinical trial patient
enrollment and the results of clinical trials; that we may be
unable to protect our intellectual property rights; and other
risks, uncertainties and assumptions, including those described
under the heading "Risk Factors" in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and NeuroOne undertakes
no obligation to revise or update any forward–looking statements
for any reason, even if new information becomes available in the
future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-to-ring-nasdaq-stock-market-closing-bell-on-november-22-301683578.html
SOURCE NeuroOne Medical Technologies Corporation